Download PDF
Semin Thromb Hemost 2004; 30(3): 351-358
DOI: 10.1055/s-2004-831048
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Interactions of Platelet Factor 4 with the Vessel Wall

Bruce S. Sachais1 , Abd Al-Roof Higazi1 , Douglas B. Cines1 , Mortimer Poncz1 , 2 , M. Anna Kowalska2 , 3
  • 1Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
  • 2Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
  • 3Assistant Professor, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Further Information

Publication History

Publication Date:
29 July 2004 (online)

    Permissions and Reprints

Platelet factor 4 (PF4) is a platelet-specific protein that is stored in platelet α granules and released following platelet activation. PF4 was the first chemokine that was isolated, but unlike other chemokines, it may not have a clear role in inflammation. Gathering evidence suggests that unlike other chemokines that bind to specific receptors, PF4’s biology depends on its unusually high affinity for heparan sulfates and other negatively charged molecules at concentrations attained in the immediate vicinity of activated platelets. There has been one report that PF4 binds to CXCR3B, a chemokine receptor isoform that may be present in some vascular beds, but the biological relevance of this single observation is not clear. We propose that the main biological role of PF4 and the basis for its presence in the α granules of all known mammalian platelets is to neutralize surface heparan sulfate side-chains of glycosaminoglycans and to optimize thrombus development at sites of vascular injury. In addition, the binding of PF4 to surface glycosaminoglycans may also underlie its angiostatic and proatherogenic properties. Additionally, PF4 binds to several other proteins that are central to thrombosis, angiogenesis, and atherogenesis. These interactions may also contribute to its biological and pathobiological effects. Certainly, future studies using in vivo models to test biological relevance of each of these proposed mechanisms by which PF4 interacts with the vasculature are needed, as are studies to define the importance of PF4 binding to CXCR3B.

KEYWORDS

Platelet factor 4 - PF4 - thrombosis - angiogenesis - atherosclerosis - chemokine - heparin

REFERENCES

  • 1 Stringer S E, Gallagher J T. Specific binding of the chemokine platelet factor 4 to heparan sulfate.  J Biol Chem. 1997;  272 20508-20514
    CrossrefPubMedGoogle Scholar
  • 2 Handin R I, Cohen H J. Purification and binding properties of human platelet factor four.  J Biol Chem. 1976;  251 4273-4282
    PubMedGoogle Scholar
  • 3 Luster A D. Chemokines-chemotactic cytokines that mediate inflammation.  N Engl J Med. 1998;  338 436-445
    CrossrefPubMedGoogle Scholar
  • 4 Fukami M H, Holmsen H, Kowalska M A, Niewiarowski S. Platelet secretion. In: Colman RW ea Hemostasis and Thrombosis. Basic Principles and Clinical Practice Philadelphia; Lippincott Williams & Wilkins 2001: 561-573
    Google Scholar
  • 5 Zhang X, Chen L, Bancroft D P, Lai C K, Maione T E. Crystal structure of recombinant human platelet factor 4.  Biochemistry. 1994;  33 8361-8366
    CrossrefPubMedGoogle Scholar
  • 6 Stuckey J A, St. Charles R, Edwards B F. A model of the platelet factor 4 complex with heparin.  Proteins. 1992;  14 277-287
    CrossrefPubMedGoogle Scholar
  • 7 Lasagni L, Francalanci M, Annunziato F et al.. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.  J Exp Med. 2003;  197 1537-1549
    CrossrefPubMedGoogle Scholar
  • 8 Niewiarowski S. Report of the working party on platelets. Platelet factor 4 (PF4), platelet protein with heparin neutralizing activity.  Thromb Haemost. 1976;  36 273-276
    PubMedGoogle Scholar
  • 9 Gewirtz A M, Calabretta B, Rucinski B, Niewiarowski S, Xu W Y. Inhibition of human megakaryocytopoiesis in vitro by platelet factor 4 (PF4) and a synthetic COOH-terminal PF4 peptide.  J Clin Invest. 1989;  83 1477-1486
    PubMedGoogle Scholar
  • 10 Zuker M, Katz I. Platelet factor 4: production, structure, and physiologic and immunologic action.  Proc Soc Exp Biol Med. 1991;  198 693-702
    PubMedGoogle Scholar
  • 11 Sharpe R J, Byers H R, Scott C F, Bauer S I, Maione T E. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4.  J Natl Cancer Inst. 1990;  82 848-853
    CrossrefPubMedGoogle Scholar
  • 12 Maione T E, Gray G S, Petro J et al.. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides.  Science. 1990;  247 77-79
    CrossrefPubMedGoogle Scholar
  • 13 Pitsilos S, Hunt J L, Mohler E R et al.. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters.  Thromb Haemost. 2003;  90 1112-1120
    PubMedGoogle Scholar
  • 14 Nassar T, Sachais B S, Akkawi S et al.. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells.  J Biol Chem. 2003;  278 6187-6193
    CrossrefPubMedGoogle Scholar
  • 15 Sachais B S, Kuo A, Nassar T et al.. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic itinerary, resulting in retention of low-density lipoprotein on the cell surface.  Blood. 2002;  99 3613-3622
    CrossrefPubMedGoogle Scholar
  • 16 Lane D A, Denton J, Flynn A M, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.  Biochem J. 1984;  218 725-732
    PubMedGoogle Scholar
  • 17 Dumenco L L, Everson B, Culp L A, Ratnoff O D. Inhibition of the activation of Hageman factor (factor XII) by platelet factor 4.  J Lab Clin Med. 1988;  112 394-400
    PubMedGoogle Scholar
  • 18 Mosnier L, Bouma B N, Griffin J H. Platelet Factor 4 upregulates protein C activation relative to TAFI activation. In: XIX Congress of The International Society on Thrombosis and Haemostasis Birmingham, UK 2003: OC376
    Google Scholar
  • 19 Slungaard A, Key N N. Platelet factor 4 stimulates thrombomodulin protein C-activating cofactor activity. A structure-function analysis.  J Biol Chem. 1994;  269 25549-25556
    PubMedGoogle Scholar
  • 20 Dudek A Z, Pennell C A, Decker T D, Young T A, Key N S, Slungaard S. Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C. A potential mechanism for enhancing generation of activated protein C.  J Biol Chem. 1997;  272 31785-31792
    CrossrefPubMedGoogle Scholar
  • 21 Slungaard A, Fernandez J A, Griffin J H et al.. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo.  Blood. 2003;  102 146-151
    CrossrefPubMedGoogle Scholar
  • 22 Esmon C. Are platelets anticoagulants? [editorial comment].  Blood. 2003;  102 3
    CrossrefPubMedGoogle Scholar
  • 23 Zhang C, Thornton M A, Kowalska M A et al.. Localization of distal regulatory domains in the megakaryocyte-specific platelet basic protein/platelet factor 4 gene locus.  Blood. 2001;  98 610-617
    CrossrefPubMedGoogle Scholar
  • 24 Eslin D E, Zhang C, Samuels K J et al.. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin.  Blood. 2004;  , In press
    PubMedGoogle Scholar
  • 25 Gewirtz A M, Zhang J, Ratajczak J et al.. Chemokine regulation of human megakaryocytopoiesis.  Blood. 1995;  86 2559-2567
    PubMedGoogle Scholar
  • 26 Kolber D L, Knisely T L, Maione T E. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4.  J Natl Cancer Inst. 1995;  87 304-309
    CrossrefPubMedGoogle Scholar
  • 27 Tanaka T, Manome Y, Wen P, Kufe D W, Fine H A. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth.  Nat Med. 1997;  3 437-442
    CrossrefPubMedGoogle Scholar
  • 28 Maione T E, Gray G S, Hunt A J, Sharpe R J. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity.  Cancer Res. 1991;  51 2077-2083
    PubMedGoogle Scholar
  • 29 Jouan V, Canron X, Alemany M et al.. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action.  Blood. 1999;  94 984-993
    PubMedGoogle Scholar
  • 30 Brown K J, Parish C R. Histidine-rich glycoprotein and platelet factor 4 mask heparan sulfate proteoglycans recognized by acidic and basic fibroblast growth factor.  Biochemistry. 1994;  33 13918-13927
    CrossrefPubMedGoogle Scholar
  • 31 Perollet C, Han Z C, Savona C, Caen J P, Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization.  Blood. 1998;  91 3289-3299
    PubMedGoogle Scholar
  • 32 Sulpice E, Bryckaert M, Lacour J, Contreres J O, Tobelem G. Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway.  Blood. 2002;  100 3087-3094
    CrossrefPubMedGoogle Scholar
  • 33 Gengrinovitch S, Greenberg S M, Cohen T et al.. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms.  J Biol Chem. 1995;  270 15059-15065
    CrossrefPubMedGoogle Scholar
  • 34 LeBreton H, Topol E, Plow E F. Evidence for a pivotal role of platelets in vascular reocclusion and restenosis.  Cardiovasc Res. 1996;  31 235-236
    CrossrefPubMedGoogle Scholar
  • 35 Harker L A. Inhibitors of platelet function in the prevention of arterial thrombosis.  Ser Haematol. 1975;  8 105-124
    PubMedGoogle Scholar
  • 36 Sinzinger H, Kaliman J, Fitscha P, O’Grady J. Diminished platelet residence time on active human atherosclerotic lesions in-vivo-evidence for an optimal dose of aspirin?.  Prostaglandins Leukot Essent Fatty Acids. 1988;  34 89-93
    CrossrefPubMedGoogle Scholar
  • 37 Sachais B S. Platelet-endothelial interactions in atherosclerosis.  Curr Atheroscler Rep. 2001;  3 412-416
    PubMedGoogle Scholar
  • 38 O’Brien J R, Etherington M D, Pashley M. Intra-platelet platelet factor 4 (IP.PF4) and the heparin-mobilisable pool of PF4 in health and atherosclerosis.  Thromb Haemost. 1984;  51 354-357
    PubMedGoogle Scholar
  • 39 Sevitt S. Platelets and foam cells in the evolution of atherosclerosis. Histological and immunohistological studies of human lesions.  Atherosclerosis. 1986;  61 107-115
    PubMedGoogle Scholar
  • 40 Chesterman C N, Berndt M C. Platelet and vessel wall interaction and the genesis of atherosclerosis.  Clin Haematol. 1986;  15 323-353
    PubMedGoogle Scholar
  • 41 Davies M J. The contribution of thrombosis to the clinical expression of coronary atherosclerosis.  Thromb Res. 1996;  82 1-32
    CrossrefPubMedGoogle Scholar
  • 42 Holvoet P, Collen D. Thrombosis and atherosclerosis.  Curr Opin Lipidol. 1997;  8 320-328
    PubMedGoogle Scholar
  • 43 Hawiger J. Mechanisms involved in platelet vessel wall interaction.  Thromb Haemost. 1995;  74 369-372
    PubMedGoogle Scholar
  • 44 Woolf N, Carstairs K C. Infiltration and thrombosis in atherogenesis. A study using immunofluorescent techniques.  Am J Pathol. 1967;  51 373-386
    PubMedGoogle Scholar
  • 45 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s.  Nature. 1993;  362 801-809
    CrossrefPubMedGoogle Scholar
  • 46 Fuhrman B, Brook G J, Aviram M. Activated platelets secrete a protein-like factor that stimulates oxidized-LDL receptor activity in macrophages.  J Lipid Res. 1991;  32 1113-1123
    PubMedGoogle Scholar
  • 47 Kruth H S. Platelet-mediated cholesterol accumulation in cultured aortic smooth muscle cells.  Science. 1985;  227 1243-1245
    PubMedGoogle Scholar
  • 48 Gawaz M, Neumann F J, Dickfeld T et al.. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells.  Circulation. 1998;  98 1164-1171
    PubMedGoogle Scholar
  • 49 Lindemann S, Tolley N D, Dixon D A et al.. Activated platelets mediate inflammatory signaling by regulated interleukin 1 {beta} synthesis.  J Cell Biol. 2001;  154 485-490
    CrossrefPubMedGoogle Scholar
  • 50 Johnson R C, Chapman S M, Dong Z M et al.. Absence of P-selectin delays fatty streak formation in mice.  J Clin Invest. 1997;  99 1037-1043
    CrossrefPubMedGoogle Scholar
  • 51 Manka D, Collins R G, Ley K, Beaudet A L, Sarembock I J. Absence of p-selectin, but not intercellular adhesion molecule-1, attenuates neointimal growth after arterial injury in apolipoprotein e-deficient mice.  Circulation. 2001;  103 1000-1005
    PubMedGoogle Scholar
  • 52 Collins R G, Velji R, Guevara N V, Hicks M J, Chan L, Beaudet A L. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice.  J Exp Med. 2000;  191 189-194
    CrossrefPubMedGoogle Scholar
  • 53 Burger P C, Wagner D D. Platelet P-selectin facilitates atherosclerotic lesion development.  Blood. 2003;  101 2661-2666
    CrossrefPubMedGoogle Scholar
  • 54 Massberg S, Brand K, Gruner S et al.. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation.  J Exp Med. 2002;  196 887-896
    CrossrefPubMedGoogle Scholar
  • 55 Huo Y, Schober A, Forlow S B et al.. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E.  Nat Med. 2003;  9 61-67
    CrossrefPubMedGoogle Scholar
  • 56 Scheuerer B, Ernst M, Durrbaum-Landmann I et al.. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages.  Blood. 2000;  95 1158-1166
    PubMedGoogle Scholar
  • 57 Deuel T F, Senior R M, Chang D, Griffin G L, Heinrikson R L, Kaiser E T. Platelet factor 4 is chemotactic for neutrophils and monocytes.  Proc Natl Acad Sci USA. 1981;  78 4584-4587
    CrossrefPubMedGoogle Scholar

M. Anna KowalskaPh.D. 

Children’s Hospital of Philadelphia, 3516 Civic Center Blvd, ARC

Rm. 316I, Philadelphia, PA 19104

Email: kowalska@email.chop.edu

      >